随着对肿瘤发病机制研究的不断深入，越来越多的新型抗肿瘤药获批上市，主要包括靶向抗肿瘤药物和免疫检查点抑制剂。新型抗肿瘤药物具有特异性高、靶向精准、疗效好、毒性低等优势，大大改善了肿瘤患者的生存质量和预后。但因其不良反应类型、监测方式等均与传统化疗药物有所区别，在不良反应预测指标、与基因多态性的关系和治疗药物监测等方面的研究尚待进一步深入。“,”With the continuous deepening of the research on tumor pathogenesis, more and more innovative oncology drugs have been approved on the market, mainly including targeted antitumor drugs and immune checkpoint inhibitors. These new antitumor drugs have the advantages of high specificity, precise targeting, good efficacy, and low toxicity to greatly improve the patient quality of life and prognosis. However, because of the different types and monitoring methods of their adverse drug reactions from those of the traditional chemotherapy ones, the research on these drugs from aspects of prediction of adverse drug reactions, the relationship between adverse drug reactions and gene polymorphisms, and the therapeutic drug monitoring are still necessary to be further researched.